Antipsychotic-Induced Weight Gain: A Comprehensive Research Synthesis
| Autor: | Joseph C. Cappelleri, Ming C. Infante, L.P. Chandler, Janet L. Mentore, Peter J. Weiden, David B. Allison, Moonseong Heo |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Olanzapine
medicine.medical_specialty Weight Gain Drug Administration Schedule Piperazines Placebos Animal science Sertindole Weight loss Internal medicine Confidence Intervals Humans Medicine Ziprasidone Clozapine Molindone Clinical Trials as Topic Risperidone business.industry Weight change Thiazoles Psychiatry and Mental health Treatment Outcome Endocrinology Psychotic Disorders Research Design medicine.symptom business Weight gain Antipsychotic Agents medicine.drug |
| Zdroj: | American Journal of Psychiatry. 156:1686-1696 |
| ISSN: | 1535-7228 0002-953X |
| DOI: | 10.1176/ajp.156.11.1686 |
| Popis: | The purpose of this study was to estimate and compare the effects of antipsychotics-both the newer ones and the conventional ones-on body weight.A comprehensive literature search identified 81 English- and non-English-language articles that included data on weight change in antipsychotic-treated patients. For each agent, a meta-analysis and random effects metaregression estimated the weight change after 10 weeks of treatment at a standard dose. A comprehensive narrative review was also conducted on all articles that did not yield quantitative information but did yield important qualitative information.Placebo was associated with a mean weight reduction of 0.74 kg. Among conventional agents, mean weight change ranged from a reduction of 0.39 kg with molindone to an increase of 3.19 kg with thioridazine. Among newer antipsychotic agents, mean increases were as follows: clozapine, 4.45 kg; olanzapine, 4.15 kg; sertindole, 2.92 kg; risperidone, 2.10 kg; and ziprasidone, 0.04 kg. Insufficient data were available to evaluate quetiapine at 10 weeks.Both conventional and newer antipsychotics are associated with weight gain. Among the newer agents, clozapine appears to have the greatest potential to induce weight gain, and ziprasidone the least. The differences among newer agents may affect compliance with medication and health risk. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|